Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 4, 1998, Pages 439-449

  Wallis, Erica J ^b   Ramsay, Lawrence E ^a   Hettiarachchi, Jayasena ^b  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; PLACEBO; SAMPATRILAT; UK 81252; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; TINNITUS; TREATMENT OUTCOME;

5'-GUANYLIC ACID; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MESYLATES; MIDDLE AGED; NEPRILYSIN; RENIN; TYROSINE;

EID: 0031666168     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90075-3     Document Type: Article

References (20)

1. Dessi-Fulgheri P, Motolese M, Di Nota G, Delfino D, Giacchetti G, Boria C, et al. Blunting of atrial natriuretic factor response to volume expansion by benazepril in hypertensive patients. J Hypertens 1989;7(suppl 6):S300-1.
2. Kohno M, Horio T, Yokokawa K, Murakawa KI, Yasunari K, Kurihara N, et al. Atrial and brain natriuretic peptides: secretion during exercise in patients with essential hypertension and modulation by acute angiotensin-converting enzyme inhibition. Clin Exper Pharmacol Physiol 1992;19:193-200.
3. Weder AB, Sekkarie MA, Takiyyuddin M, Schork NJ, Julius S. Antihypertensive and hypotensive effects of atrial natriuretic factor in man. Hypertension 1987;10:582-9.
4. Richards AM, Nicholls MG, Ikram H, Webster MWI, Yandle TG, Espiner EA. Renal, haemodynamic and hormonal effects of human alpha atrial natriuretic peptide in healthy volunteers. Lancet 1985;1:545-8.
5. Weidmann P, Hellmueller B, Uehlinger DE, Lang RE, Gnaedinger MP, Hasler L, et al. Plasma levels and cardiovascular, endocrine, and excretory effects of atrial natriuretic peptide during different sodium intakes in man. J Clin Endocrinol Metab 1986;62:1027-36.
6. Cuneo RC, Espiner EA, Nicholls G, Yandle TG, Joyce SL, Gilchrist NL. Renal, haemodynamic, and hormonal responses to atrial natriuretic peptide infusions in normal man, and effect of sodium intake. J Clin Endocrinol Metab 1986;63:946-53.
7. Anderson JV, Donckier NN, Payne NN, Beacham J, Slater JDH, Bloom SR. Atrial natriuretic peptide: evidence of action as a natriuretic hormone at physiological plasma concentrations in man. Clin Sci 1987;72:305-12.
8. Kleinert HD, Maack T, Atlas SA, Januszewicz A, Sealey JE, Laragh J. Atrial natriuretic factor inhibits angiotensin, norepinephrine-, and potassium-induced vascular contractility. Hypertension 1984;6(suppl I):I143-7.
9. Hughes A, Thom S, Goldberg P, Martin G, Sever P. Direct effect of α-human atrial natriuretic peptide on human vasculature in vivo and in vitro. Clin Sci 1988;74:207-11.
10. Baldonicini R, Ferri C, De Siata L, Coassin S, Bellini C, Cacciafesta M, et al. Effects of atrial natriuretic factor on plasma prorenin levels in hypertensive males. Clin Exper Hypertens 1994;16:283-302.
11. O'Connell JE, Jardine AG, Dsavidson G, Connell JMC. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 1992;10:271-7.
12. Bevan EG, Connell JMC, Doyle J, Carmichael HA, Davies DL, Lorimer AR, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607-13.
13. Singer DRJ, Markandu ND, Buckley MG, Miller MA, Sagnella GA, MacGregor GA. Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension. Hypertension 1991;18:798-804.
14. Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H, et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11:407-16.
15. Nakamura M, Arakawa N, Kawata Y, Kato M. Effects of low dose infusion of atrial natriuretic factor on acute inhibition of angiotensin converting enzyme in normal men. Clin Exper Pharmacol Physiol 1990;17:17-22.
16. Hodsman GP, Isles CG, Murray GD, Usherwood TP, Web DJ, Robertson JIS. Factors related to first dose hypotensive effect of captopril: prediction and treatment. BMJ 1983;286:832-4.
17. Yeo WW, Foster G, Ramsay LE. Prevalence of persistent cough during enalapril treatment: controlled study versus nifedipine. QJM 1991;293:763-70.
18. Yeo WW, Ramsay LE. Persistent dry cough with enalapril: incidence depends on method used. J Hum Hypertens 1990;4:517-20.
19. Yeo WW, Higgins KS, Foster G, Jackson PR, Ramsay LE. Effect of dose adjustment on enalapril-induced cough and the response to inhaled capsaicin. Br J Clin Pharmacol 1995;39:271-6.
20. Biollaz J, Burnier M, Turini GA, Brunner DB, Porchet M, Gomez HJ, et al. Three new long-acting convertingenzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther 1981;29:665-70.